Voruciclib, a Potent CDK4/6 Inhibitor, Antagonizes ABCB1 and ABCG2-Mediated Multi-Drug Resistance in Cancer Cells | Zendy

Pranav Gupta | Zendy; Yunkai Zhang | Zendy; Xiaoyu Zhang | Zendy; YiJun Wang | Zendy; Kimberly Lu | Zendy; Timothy L. Hall | Zendy; Richard Peng | Zendy; DongHua Yang | Zendy; Ni Xie | Zendy; ZheSheng Chen | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Voruciclib, a Potent CDK4/6 Inhibitor, Antagonizes ABCB1 and ABCG2-Mediated Multi-Drug Resistance in Cancer Cells

Author(s) -

Pranav Gupta,

Yunkai Zhang,

Xiaoyu Zhang,

YiJun Wang,

Kimberly Lu,

Timothy L. Hall,

Richard Peng,

DongHua Yang,

Ni Xie,

ZheSheng Chen

Publication year - 2018

Publication title -

cellular physiology and biochemistry

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.486

H-Index - 87

eISSN - 1421-9778

pISSN - 1015-8987

DOI - 10.1159/000487578

Subject(s) - abcg2 , cytotoxicity , rhodamine 123 , atp binding cassette transporter , paclitaxel , abcc1 , efflux , chemistry , pharmacology , intracellular , doxorubicin , cancer cell , multiple drug resistance , mtt assay , flow cytometry , apoptosis , microbiology and biotechnology , biology , biochemistry , transporter , cancer , in vitro , chemotherapy , genetics , gene , antibiotics

The overexpression of ATP-Binding Cassette (ABC) transporters has known to be one of the major obstacles impeding the success of chemotherapy in drug resistant cancers. In this study, we evaluated voruciclib, a CDK 4/6 inhibitor, for its chemo-sensitizing activity in ABCB1- and ABCG2- overexpressing cells.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research